24/7 Market News Snapshot 28 July, 2025 – Alterity Therapeutics Limited American Depositary Shares (NASDAQ:ATHE)

July 28, 2025

DENVER, Colo., 28 July, 2025 (www.247marketnews.com) – (NASDAQ:ATHE) are discussed in this article.
Alterity Therapeutics Limited is currently navigating a challenging market environment, with its pre-market trading price at $6.264, reflecting a decline of approximately 4.37% from the previous close of $6.550. With a notable trading volume of 698.63K shares, heightened investor activity indicates increased volatility. Key support is identified around $6.20, where a breach may lead to further downturns, while resistance is observed at $6.55. Given the negative momentum, investor caution is advised, and close monitoring of upcoming trading sessions will be essential to assess market sentiment and the potential for trend reversals.

Amidst this backdrop, Alterity is also celebrating positive topline results from its ATH434-202 open-label Phase 2 clinical trial, which highlights ATH434’s clinical benefits for patients with advanced Multiple System Atrophy (MSA). This trial showcased significant advancements for participants, underscoring ATH434’s promise to modify the disease’s trajectory—a critical achievement for a condition that currently lacks effective treatments.

Results indicate that ATH434 markedly improved patient outcomes as measured by the Modified Unified MSA Rating Scale, leading to a significant reduction in disease progression when compared to historical controls. Approximately 30% of participants experienced stabilization of their neurological symptoms, a noteworthy finding given the condition’s typical progression. Furthermore, ATH434 exhibited potential for stabilizing symptoms of orthostatic hypotension, enhancing its therapeutic profile.

Neuroimaging data revealed that ATH434 slowed brain atrophy in regions impacted by MSA, validating its target engagement and the efficacy observed in preclinical studies. David Stamler, CEO of Alterity, expressed optimism regarding these results, reinforcing the company’s commitment to advancing ATH434 as a therapeutic option for those affected by this challenging neurodegenerative disorder. With the compelling outcomes from the ATH434-202 study, Alterity is poised to make significant advancements in the treatment landscape for MSA.

Related news for (ATHE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.